Уважаемые пользователи!
Мы рады представить вам новую версию сайта с улучшенным интерфейсом и новыми возможностями.
Приглашаем вас ознакомиться и поделиться обратной связью. Спасибо, что вы с нами!
Попробовать!

Impact of obesity on response to thienopyridine and bleeding risk in patients treated after acute coronary syndrome by clopidogrel or prasugrel

06.09.20131787
Variability of response to thienopyridine has been described for both clopidogrel and prasugrel.

Reduced kidney function and anemia as risk factors for new onset AF

05.09.20131887
Each of chronic kidney disease (CKD) and anemia is a potential independent risk factor for cardiovascular disease (CVD); however, reduced kidney function, anemia, and its relationship have not been fully evaluated for the incidence of atrial fibrillation (AF).

Gender Data Forum: Are DES Safer and More Effective Than Bare Metal Stents in Women?

04.09.20131603
The use of drug-eluting stents (DES) in women is more effective and safe than using bare-metal stents during long-term follow-up, according to a study released on Sept. 2 during the ESC Congress 2013 and simultaneously published in The Lancet.

2013 ESC Gold Medal award winners

03.09.20132661
Two ESC gold medallists for 2013: Evgeny Chazov and Douglas Zipes receive ESC honours.

RAFT: Beta Blocker Therapy in Congestive Heart Failure Patients With LVEF

03.09.20131833
Use of beta blocker therapy to treat congestive heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF) remains paramount, with benefits independent of those of newer CHF therapies, according to results of the RAFT Study presented on Sept. 2 during the ESC Congress 2013.

Randomized Trial of Preventive Angioplasty in Myocardial Infarction

02.09.20131877
In acute ST-segment elevation myocardial infarction (STEMI), the use of percutaneous coronary intervention (PCI) to treat the artery responsible for the infarct (infarct, or culprit, artery) improves prognosis.

Macitentan Cuts Morbidity, Death in Pulmonary Arterial HTN

30.08.20132070
For patients with pulmonary arterial hypertension, the new dual endothelin-receptor antagonist macitentan is associated with reductions in morbidity and mortality, according to a study published in the Aug. 29 issue of the New England Journal of Medicine.
Данный сайт и вся информация на нём предназначена для медицинских работников. Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.